Injury - 2026-11-04 - Journal Article
Aspirin is safe and effective for prevention of deep vein thrombosis following acetabular fracture surgery.
Dinesh A, Poursalehian M, Billow D, Peirish RW, Cereijo C, Padubidri A, Patterson B, Vallier HA
Topics
Key Takeaway
Aspirin was associated with significantly lower odds of DVT at 90 days compared to other anticoagulants following acetabular fracture surgery (2.56% vs. 4.34%; OR 0.577, p=0.018) after propensity score matching.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This study asked whether aspirin is as safe and effective as other anticoagulants for DVT prevention after acetabular fracture ORIF, using a global EHR/claims network database with propensity score-matched cohorts. Aspirin demonstrated significantly lower DVT rates at 14, 30, and 90 days (2.56% vs. 4.34% at 90 days; OR 0.577) and fewer 90-day ED visits (OR 0.741), with no differences in deep infection, stroke, or readmission. Aspirin utilization increased from 7.2% in 2014 to 39.5% in 2025.
Key Limitation
The database design cannot distinguish symptomatic from screening-detected DVT, making it impossible to determine whether the DVT rate difference reflects true thrombotic burden or differential surveillance practices between cohorts.
Original Abstract
BACKGROUND
Patients with acetabular fractures are at significant risk for venous thromboembolism (VTE), yet the optimal chemoprophylactic agent remains undefined. Emerging evidence from elective arthroplasty and general orthopaedic trauma populations suggests that aspirin (ASA) may be a safe and effective alternative to traditional anticoagulants. The purpose of this study was to evaluate the safety and efficacy of ASA compared to other anticoagulants for deep vein thrombosis (DVT) prevention following acetabular fracture surgery.
METHODS
A retrospective cohort analysis was performed using a global, web-based health research network that provides on-demand access to de-identified, real-world data from electronic health records and claims. Adult patients (≥18 years) who underwent surgical treatment for acetabular fractures between January 2014 and December 2025 and received VTE prophylaxis within 14 days of surgery were identified. Patients were stratified into ASA (n = 1189) and other anticoagulant (n = 5478) cohorts. Propensity score matching (1:1) was performed to balance baseline characteristics, yielding 1174 patients per cohort. Rates and odds of DVT, emergency department (ED) visits, deep infection, stroke, and readmission were assessed at 14-, 30-, and 90-day postoperative intervals. Temporal trends in VTE prophylaxis utilization were also analyzed.
RESULTS
Compared to other anticoagulants, ASA was associated with significantly lower odds of DVT at 14 days (1.11% vs. 2.22%; odds ratio [OR]: 0.494; 95% confidence interval [CI]: 0.253-0.967; P = 0.036), 30 days (1.45% vs. 2.73%; OR: 0.524; 95% CI: 0.290-0.950; P = 0.030), and 90 days (2.56% vs. 4.34%; OR: 0.577; 95% CI: 0.365-0.913; P = 0.018). ASA was also associated with significantly lower odds of ED visits at 90 days (OR: 0.741; 95% CI: 0.570-0.963; P = 0.024). There were no significant differences in deep infection, stroke, or readmission rates. ASA utilization increased from 7.2% in 2014-39.5% in 2025.
CONCLUSIONS
ASA is safe and effective for DVT prevention following acetabular fracture surgery and is associated with fewer ED visits compared to other anticoagulants. These findings support the growing adoption of ASA as a VTE prophylactic agent in the acetabular fracture population.